ACIU GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
AC Immune SA
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Values in USD · ADR · Reports in CHF
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features sixteen therapeutic and diagnostic programs, including five in Phase 2 development and one in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties. SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU. The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
Did you know?
Currently operating at a negative 1789.5% profit margin.
Current Price
$2.98
-1.65%Profile
Valuation (TTM)
Market Cap$303.19M
P/E-3.58
EV—
P/B5.34
Shares Out101.74M
P/Sales65.50
Revenue$4.63M
EV/EBITDA—
AC Immune SA (ACIU) Quality Analysis
ACIU Profitability
Profitability trend analysis coming soon
ACIU Growth
Growth trend analysis coming soon
ACIU Financial Health
Financial health indicators coming soon
ACIU Quality & Fundamental Analysis
AC Immune SA (ACIU) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates AC Immune SA's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
AC Immune SA has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -1789.46% and a return on equity (ROE) of -145.79%. Return on assets (ROA) stands at -42.42%.
The debt-to-equity ratio is 0.10, with a current ratio of 1.02. Operating margin is -1940.05%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether AC Immune SA is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.